Emfizatamab is under clinical development by Systimmune and currently in Phase II for Central Nervous System (CNS) Cancer. According to GlobalData, Phase II drugs for Central Nervous System (CNS) Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Emfizatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emfizatamab (GNC-038) is under development for the treatment of recurrent or refractory non-Hodgkin lymphoma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), leukemia, relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL), NK/T-cell lymphoma, angioimmunoblastic T-cell lymphoma and solid tumor. The drug candidate is a tetra-specific antibody which acts by targeting programmed cell death 1 ligand 1 (PD-L1), CD19, 41BB and CD3. It is administered through intravenous route.
Systimmune is a biopharmaceutical company that develops novel therapies for the treatment of cancer. The company’s technology platforms for the discovery and development of novel bio-therapeutics include antibody discovery platform to manufacture target-specific IgG producing B cells using novel miniaturized immuno-assays; process development platform to manufacture bio-therapeutics and multi-specific antibody engineering platforms. Its pipeline portfolio include bi-specific antibodies, antibody conjugates, and immuno-oncology products for the treatment of non-small cell lung cancer, glioblastoma, colon, neck, head, breast, nasopharyngeal, kidney and liver cancers. These antibodies act through systematic intervention to trigger the immune response on the cancer cells. Systimmune is headquartered in Redmond, Washington, the US.
For a complete picture of Emfizatamab’s drug-specific PTSR and LoA scores, buy the report here.